Longieva has been developing novel therapeutics for validated targets for CNS disorders with utility in neurodegeneration (such as Alzheimer's and Parkinson's) and addictive disorders. We believe the therapy also offers the potential to treat some psychiatric disorders. These projects are based on the composition of novel chemical entities (small molecules) and associated IP. Exciting new data generated in Stanford lab supports the vast potential of these projects. Longieva Therapeutics has been formed to advance these projects and are now initiating funding discussions with potential partners. One of our programs is fully supported by NIH non-dilutive funding from the Blueprint Neurotherapeutics network for preclinical and clinical development up to phase III for drug addiction indications. This is our most advanced program. We plan to develop the utilities in other CNS indications through funding activity and partnership.